Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status

British Journal of Clinical Pharmacology

Volumn 61, Issue 3, 2006, Pages 309-314

  Uno, Tsukasa ^a,b,c   Shimizu, Mikiko ^b   Yasui Furukori, Norio ^b   Sugawara, Kazunobu ^c   Tateishi, Tomonori ^b  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c HIROSAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

CYP2C19; Fluvoxamine; Rabeprazole

Indexed keywords

CYTOCHROME P450 2C19; DRUG METABOLITE; DRUG METABOLIZING ENZYME; ETHER DERIVATIVE; FLUVOXAMINE MALEATE; PLACEBO; RABEPRAZOLE; RABEPRAZOLE THIOETHER; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SCREENING; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT WITHDRAWAL; VOLUNTEER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; FLUVOXAMINE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; SEROTONIN UPTAKE INHIBITORS;

EID: 33644908781     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02556.x     Document Type: Article

References (25)

1. Prakash A Faulds D Rabeprazole Drugs 1998 55 261 7
2. Williams MP Pounder RE Review article. The pharmacology of rabeprazole Aliment Pharmacol Ther 1999 13 3 10
3. Andersson T Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole Clin Pharmacokinet 1996 31 9 28
4. Ishizaki T Horai Y Review article: Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole Aliment Pharmacol Ther 1999 13 27 36
5. Furuta T Ohashi K Kosuge K Zhao XJ Takashima M Kimura M Nishimoto M Hanai H Kaneko E Ishizaki T CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans Clin Pharmacol Ther 1999 65 552 61
6. Furuta T Shirai N Xiao F Ohashi K Ishizaki T Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19 Clin Pharmacol Ther 2001 70 484 92
7. Yasuda S Horai Y Tomono Y Nakai H Yamato C Manabe K Kobayashi K Chiba K Ishizaki T Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status Clin Pharmacol Ther 1995 58 143 54
8. VandenBranden M Ring BJ Binkley SN Wrighton SA Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton inhibitor Pharmacogenetics 1996 6 81 91
9. Horai Y Kimura M Furuie H Matsuguma K Irie S Koga Y Nagahama T Murakami M Matsui T Yao T Urae A Ishizaki T Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes Aliment Pharmacol Ther 2001 15 793 803
10. Shirai N Furuta T Moriyama Y Okochi H Kobayashi K Takashima M Xiao F Kosuge K Nakagawa K Hanai H Chiba K Ohashi K Ishizaki T Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH Aliment Pharmacol Ther 2001 15 1929 37
11. Ieiri I Kishimoto Y Okochi H Momiyama K Morita T Kitano M Morisawa T Fukushima Y Nakagawa K Hasegawa J Otsubo K Ishizaki T Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism Eur J Clin Pharmacol 2001 57 485 92
12. Sugimoto M Furuta T Shirai N Kajimura M Hishida A Sakurai M Ohashi K Ishizaki T Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status Clin Pharmacol Ther 2004 76 290 301
13. Shimatani T Inoue M Kuroiwa T Horikawa Y Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression Aliment Pharmacol Ther 2004 19 113 22
14. Figgitt DP McClellan KJ Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders Drugs 2000 60 925 54
15. Hemeryck A Belpaire FM Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update Curr Drug Metab 2002 3 13 37
16. Christensen M Tybring G Mihara K Yasui-Furukori N Carrillo JA Ramos SI Andersson K Dahl ML Bertilsson L Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19) Clin Pharmacol Ther 2002 71 141 52
17. Spina E Scordo MG Clinically significant drug interactions with antidepressants in the elderly Drugs Aging 2002 19 299 320
18. Yasui-Furukori N Takahata T Nakagami T Yoshiya G Inoue Y Kaneko S Tateishi T Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes Br J Clin Pharmacol 2004 57 487 94
19. Yasui-Furukori N Saito M Uno T Takahata T Sugawara K Tateishi T Effects of fluvoxamine on lansoprazole pharmacokinetics in rela-tion to CYP2C19 genotypes J Clin Pharmacol 2004 44 1223 9
20. De Morais SM Wilkinson GR Blaisdell J Meyer UA Nakamura K Goldstein JA Identification of a new genetic defect responsible for the polymorphism of (S) -mephenytoin metabolism in Japanese Mol Pharmacol 1994 46 594 8
21. Uno T Yasui-Furukori N Shimizu M Sugawara K Tateishi T Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study JChromatogr B 2005; in press
22. Furuta T Ohashi K Kamata T Takashima M Kosuge K Kawasaki T Hanai H Kubota T Ishizaki T Kaneko E Effects of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer Ann Intern Med 1998 129 1027 30
23. Furuta T Shirai N Takashima M Xiao F Hanai H Sugimura H Ohashi K Ishizaki T Kaneko E Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin Clin Pharmacol Ther 2001 69 158 68
24. Furuta T Shirai N Takashima M Xiao F Hanai H Nakagawa K Sugimura H Ohashi K Ishizaki T Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin Pharmacogenetics 2001 11 341 8
25. Sugimoto M Furuta T Shirai N Nakamura A Kajimura M Hishida A Ohashi K Ishizaki T Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype Clin Pharmacol Ther 2005 77 302 11